139 related articles for article (PubMed ID: 24262662)
1. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.
Van Maerken T; Rihani A; Van Goethem A; De Paepe A; Speleman F; Vandesompele J
Cancer Lett; 2014 Mar; 344(2):157-65. PubMed ID: 24262662
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the therapeutic perspectives of Nutlin-3.
Secchiero P; Bosco R; Celeghini C; Zauli G
Curr Pharm Des; 2011; 17(6):569-77. PubMed ID: 21391907
[TBL] [Abstract][Full Text] [Related]
3. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
6. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
Shen H; Maki CG
Curr Pharm Des; 2011; 17(6):560-8. PubMed ID: 21391906
[TBL] [Abstract][Full Text] [Related]
9. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
12. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.
Ghassemifar S; Mendrysa SM
Neurosci Lett; 2012 Mar; 513(1):106-10. PubMed ID: 22343310
[TBL] [Abstract][Full Text] [Related]
13. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.
Tisato V; Norcio A; Voltan R; Celeghini C; Zella D; Secchiero P
Curr Med Chem; 2013; 20(17):2226-36. PubMed ID: 23458617
[TBL] [Abstract][Full Text] [Related]
14. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
15. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.
Huang B; Deo D; Xia M; Vassilev LT
Mol Cancer Res; 2009 Sep; 7(9):1497-509. PubMed ID: 19737973
[TBL] [Abstract][Full Text] [Related]
19. Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.
Aizu W; Belinsky GS; Flynn C; Noonan EJ; Boes CC; Godman CA; Doshi B; Nambiar PR; Rosenberg DW; Giardina C
Biochem Pharmacol; 2006 Oct; 72(8):981-91. PubMed ID: 16949053
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
